In a recent study published in ACS Applied Nano Materials, researchers from ISOF-CNR and the University of Padova developed an innovative nanoplatform for cancer therapy. The team engineered manganese dioxide (MnO₂)-decorated albumin nanoparticles co-loaded with two bioresponsive prodrugs: paclitaxel, a chemotherapeutic agent, and NLG919, an IDO1 inhibitor.
These nanoparticles are designed to selectively release their cargo in the tumor microenvironment, simultaneously alleviating tumor hypoxia and enhancing immune activation.
The system effectively induces immunogenic cell death (ICD), inhibits the IDO1 enzyme, and promotes the repolarization of tumor-associated macrophages from a pro-tumoral (M2) to an anti-tumoral (M1) phenotype. This multi-pronged approach opens promising avenues for next-generation cancer therapies targeting both tumor cells and their microenvironment.
Read more: https://pubs.acs.org/doi/full/10.1021/acsanm.5c00589